{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T14:19:10Z","timestamp":1740147550756,"version":"3.37.3"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,8,14]],"date-time":"2015-08-14T00:00:00Z","timestamp":1439510400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2015,8,14]],"date-time":"2015-08-14T00:00:00Z","timestamp":1439510400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U01 DK082863"],"award-info":[{"award-number":["U01 DK082863"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1007\/s12072-015-9659-4","type":"journal-article","created":{"date-parts":[[2015,8,13]],"date-time":"2015-08-13T08:23:56Z","timestamp":1439454236000},"page":"139-146","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Admissions for hepatitis B reactivation in patients receiving immunosuppressive therapy remain unchanged from 1999 to 2014"],"prefix":"10.1007","volume":"10","author":[{"given":"Arpan","family":"Patel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suna","family":"Yapali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna S. F.","family":"Lok","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,8,14]]},"reference":[{"issue":"4","key":"9659_CR1","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1053\/gast.2001.22461","volume":"120","author":"RP Perillo","year":"2001","unstructured":"Perillo RP. Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease. Gastroenterology 2001;120(4):1009\u20131022","journal-title":"Gastroenterology"},{"key":"9659_CR2","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1002\/hep.26718","volume":"59","author":"C Hsu","year":"2014","unstructured":"Hsu C, Tsou HH, Lin SJ, et al. Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: a prospective study. Hepatology 2014;59:2092\u20132100","journal-title":"Hepatology"},{"key":"9659_CR3","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1093\/annonc\/mdq583","volume":"22","author":"AM Evens","year":"2011","unstructured":"Evens AM, Jovanovic BD, Su YC, et al. Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports. Ann Oncol 2011;22:1170\u20131180","journal-title":"Ann Oncol"},{"issue":"10","key":"9659_CR4","doi-asserted-by":"publisher","first-page":"743","DOI":"10.7326\/0003-4819-156-10-201205150-00013","volume":"156","author":"AS Lok","year":"2012","unstructured":"Lok AS, Ward JW, Perrillo RP, McMahon BJ, Liang TJ. Reactivation of hepatitis B during immunosuppressive therapy: potentially fatal yet preventable. Ann Intern Med 2012;156(10):743\u2013745","journal-title":"Ann Intern Med"},{"key":"9659_CR5","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/0016-5085(91)70034-U","volume":"100","author":"P Marcellin","year":"1991","unstructured":"Marcellin P, Giostra E, Martinot-Peignoux M, et al. Redevelopment of hepatitis B surface antigen after renal transplantation. Gastroenterology 1991;100:1432\u20131434","journal-title":"Gastroenterology"},{"key":"9659_CR6","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1159\/000186140","volume":"56","author":"G Rostoker","year":"1990","unstructured":"Rostoker G, Rosenbaum J, Ben Maadi A, et al. Reactivation of hepatitis B virus by corticosteroids in a case of idiopathic nephritic syndrome. Nephron 1990;56:224","journal-title":"Nephron"},{"key":"9659_CR7","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1136\/gut.2004.040675","volume":"53","author":"M Esteve","year":"2004","unstructured":"Esteve M, Saro C, Gonzalez-Huix F, Suarez F, Forne M, Viver JM. Chronic hepatitis B reactivation following infliximab therapy in Crohn\u2019s disease patients: need for primary prophylaxis. Gut 2004;53:1363\u20131365","journal-title":"Gut"},{"key":"9659_CR8","doi-asserted-by":"publisher","unstructured":"Ifuku H, Kusumoto S, Tanaka Y, et al. Fatal reactivation of hepatitis B virus infection in a patient with adult T-cell leukemia-lymphoma receiving the anti-CC chemokine receptor 4 antibody mogamulizumab. Hepatol Res 2015. doi: 10.1111\/hepr.12513","DOI":"10.1111\/hepr.12513"},{"key":"9659_CR9","doi-asserted-by":"publisher","first-page":"519","DOI":"10.7326\/0003-4819-148-7-200804010-00008","volume":"148","author":"R Loomba","year":"2008","unstructured":"Loomba R, Rowley A, Wesley R, et al. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med 2008;148:519\u2013528","journal-title":"Ann Intern Med"},{"issue":"5 Suppl","key":"9659_CR10","doi-asserted-by":"publisher","first-page":"S156","DOI":"10.1002\/hep.22945","volume":"49","author":"JH Hoofnagle","year":"2009","unstructured":"Hoofnagle JH. Reactivation of hepatitis B. Hepatology 2009;49(5 Suppl):S156\u2013S165","journal-title":"Hepatology"},{"issue":"RR-8","key":"9659_CR11","first-page":"1","volume":"57","author":"CM Weinbaum","year":"2008","unstructured":"Weinbaum CM, Williams I, Mast EE, Centers for Disease Control and Prevention (CDC), et al. Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recomm Rep 2008;57(RR-8):1\u201320","journal-title":"MMWR Recomm Rep"},{"key":"9659_CR12","doi-asserted-by":"publisher","first-page":"104","DOI":"10.7326\/0003-4819-150-2-200901200-00100","volume":"150","author":"MF Sorrell","year":"2009","unstructured":"Sorrell MF, Belongia EA, Costa J, et al. National Institutes of Health consensus development conference statement: management of hepatitis B. Ann Intern Med 2009;150:104\u2013110","journal-title":"Ann Intern Med"},{"key":"9659_CR13","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1002\/hep.23190","volume":"50","author":"AS Lok","year":"2009","unstructured":"Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009;50:661\u2013662","journal-title":"Hepatology"},{"key":"9659_CR14","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.jhep.2012.02.010","volume":"57","author":"European Association For The Study Of The Liver","year":"2012","unstructured":"European Association For The Study Of The Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012;57:167","journal-title":"J Hepatol"},{"key":"9659_CR15","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1053\/j.gastro.2014.10.038","volume":"148","author":"RP Perrillo","year":"2015","unstructured":"Perrillo RP, Gish R, Falck-Ytter YT. American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology 2015;148:221","journal-title":"Gastroenterology"},{"key":"9659_CR16","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/1471-230X-14-31","volume":"14","author":"M Masarone","year":"2014","unstructured":"Masarone M, De Renzo A, La Mura V, et al. Management of the HBV reactivation in isolated HBcAb positive patients affected with Non Hodgkin Lymphoma. BMC Gastroenterol 2014;14:31","journal-title":"BMC Gastroenterol"},{"issue":"1","key":"9659_CR17","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.clinre.2011.07.018","volume":"36","author":"P Papamichalis","year":"2012","unstructured":"Papamichalis P, Alexiou A, Boulbou M, et al. Reactivation of resolved hepatitis B virus infection after immunosuppression: is it time to adopt pre-emptive therapy? Clin Res Hepatol Gastroenterol 2012;36(1):84\u201393","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"26","key":"9659_CR18","doi-asserted-by":"publisher","first-page":"3167","DOI":"10.1200\/JCO.2011.40.7510","volume":"30","author":"U Zurawska","year":"2012","unstructured":"Zurawska U, Hicks LK, Woo G, et al. Hepatitis B virus screening before chemotherapy for lymphoma: a cost-effectiveness analysis. J Clin Oncol 2012;30(26):3167\u20133173","journal-title":"J Clin Oncol"},{"issue":"3","key":"9659_CR19","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1111\/j.1346-8138.2011.01434.x","volume":"39","author":"YT Cho","year":"2012","unstructured":"Cho YT, Chen CH, Chiu HY, et al. Use of anti-tumor necrosis factor-\u03b1 therapy in hepatitis B virus carriers with psoriasis or psoriatic arthritis: a case series in Taiwan. J Dermatol 2012;39(3):269\u2013273","journal-title":"J Dermatol"},{"issue":"1","key":"9659_CR20","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1002\/hep.27716","volume":"62","author":"M Barone","year":"2015","unstructured":"Barone M, Notarnicola A, Lopalco G. Safety of long-term biologic therapy in rheumatologic patients with a previously resolved hepatitis B viral infection. Hepatology 2015;62(1):40\u201346","journal-title":"Hepatology"},{"key":"9659_CR21","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.jaad.2013.08.049","volume":"70","author":"K Motaparthi","year":"2014","unstructured":"Motaparthi K, Stanisic V, Van Voorhees AS, et al. From the Medical Board of the National Psoriasis Foundation: recommendations for screening for hepatitis B infection prior to initiating anti-tumor necrosis factor-alfa inhibitors or other immunosuppressive agents in patients with psoriasis. J Am Acad Dermatol 2014;70:178","journal-title":"J Am Acad Dermatol"},{"key":"9659_CR22","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1002\/art.23721","volume":"59","author":"K Saag","year":"2008","unstructured":"Saag K, Teng G, Patkar N, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum (Arthritis Care Res) 2008;59:762\u2013784","journal-title":"Arthritis Rheum (Arthritis Care Res)"},{"issue":"1","key":"9659_CR23","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1053\/j.gastro.2014.10.039","volume":"148","author":"KR Reddy","year":"2015","unstructured":"Reddy KR, et al. American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology 2015;148(1):215\u2013219","journal-title":"Gastroenterology"},{"key":"9659_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/hepr.12269","volume":"44","author":"Drafting Committee for Hepatitis Management Guidelines and the Japan Society of Hepatology","year":"2014","unstructured":"Drafting Committee for Hepatitis Management Guidelines and the Japan Society of Hepatology. JSH Guidelines for the management of hepatitis B virus infection. Hepatol Res 2014;44:1\u201358","journal-title":"Hepatol Res"},{"key":"9659_CR25","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.1200\/JCO.2010.30.0673","volume":"28","author":"AS Artz","year":"2010","unstructured":"Artz AS, Somerfield MR, Feld JJ, et al. American Society of Clinical Oncology provisional clinical opinion: chronic hepatitis B virus infection screening in patients receiving cytotoxic chemotherapy for treatment of malignant diseases. J Clin Oncol 2010;28:3199\u20133202","journal-title":"J Clin Oncol"},{"key":"9659_CR26","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/j.1365-2036.2009.04158.x","volume":"31","author":"TT Tran","year":"2010","unstructured":"Tran TT, Rakoski MO, Martin P, Poordad F. Screening for hepatitis B in chemotherapy patients: survey of current oncology practices. Aliment Pharmacol Ther 2010;31:240\u2013246","journal-title":"Aliment Pharmacol Ther"},{"key":"9659_CR27","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1200\/JOP.2010.000133","volume":"7","author":"FL Day","year":"2011","unstructured":"Day FL, Link E, Thursky K, Rischin D. Current hepatitis B screening practices and clinical experience of reactivation in patients undergoing chemotherapy for solid tumors: a nationwide survey of medical oncologists. J Oncol Pract 2011;7:141\u2013147","journal-title":"J Oncol Pract"},{"key":"9659_CR28","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1002\/hep.21024","volume":"43","author":"JW Jang","year":"2006","unstructured":"Jang JW, Choi JY, Bae SH, et al. A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo-lipiodolization. Hepatology 2006;43:233","journal-title":"Hepatology"},{"key":"9659_CR29","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1053\/j.gastro.2003.09.026","volume":"125","author":"GK Lau","year":"2003","unstructured":"Lau GK, Yiu HH, Fong DY, et al. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology 2003;125:1742","journal-title":"Gastroenterology"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-015-9659-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12072-015-9659-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-015-9659-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-015-9659-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T14:23:53Z","timestamp":1718029433000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12072-015-9659-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8,14]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["9659"],"URL":"https:\/\/doi.org\/10.1007\/s12072-015-9659-4","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"type":"print","value":"1936-0533"},{"type":"electronic","value":"1936-0541"}],"subject":[],"published":{"date-parts":[[2015,8,14]]},"assertion":[{"value":"2 June 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Arpan Patel and Suna Yapali have nothing to disclose. Anna Lok has received research grants from Bristol-Myers Squibb and Gilead Sciences and has served on advisory board of Gilead Science.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}